How Estrogen Keeps Lead—and Heart Attacks—in Check

For over a century, coronary heart disease has ruled the global charts as the leading cause of death. In textbooks, clinics, and conference halls, it’s often portrayed as a man’s disease. Statistically, that’s not entirely wrong—at least not at first glance. Men do tend to develop heart disease earlier. But around the age of menopause, women’s rates catch up—and then some.

Before menopause, women enjoy a curious advantage. Their risk of coronary heart disease—of heart attacks— is roughly half that of men the same age. This advantage, however, begins to fade as estrogen levels decline. After menopause, the risk rises sharply, and older women now make up a growing share of heart disease cases. For decades, researchers have pointed to estrogen as the likely reason for this discrepancy. But despite widespread agreement that estrogen does something helpful, we still don’t really know how it works.

The prevailing theories are familiar. Estrogen, we’re told, boosts HDL (the “good” cholesterol), lowers LDL (the “bad” kind), and improves vascular function. These mechanisms make sense—and they may well be true—but they don’t tell the whole story. For one, they don’t explain why clinical trials of hormone therapy in older women failed to show cardiovascular benefits. Nor do they clarify why timing seems to matter so much.

But what if we’ve been looking at the estrogen story too narrowly? What if estrogen’s protective effects aren’t just about what it does directly to blood vessels, but also about what it helps to remove from the bloodstream?

Let’s consider a less glamorous, less well-known character in this drama: lead.

A Familiar Villain with a New Motive

Lead is an old nemesis. Most people associate it with brain damage in children or scandals about drinking water. But fewer realize that lead is also toxic to the heart. It raises blood pressure, damages blood vessels, alters cholesterol, and increases the risk of heart attacks. And unlike some risk factors, lead doesn’t have a safe level. The damage starts early and scales with exposure.

In a 2018 study using data from the U.S. National Health and Nutrition Examination Survey, researchers estimated that low-level lead exposure was responsible for 250,000 deaths from cardiovascular disease annually in the United States alone. Blood lead levels as low as 10 μg/L (10 parts-per-billion) were associated with increased mortality—and too many Americans still carry levels above that.

Other studies have echoed the alarm. In a large meta-analysis covering over 90,000 people, those with the highest blood lead concentrations had nearly double the risk of coronary heart disease compared to those with the lowest. Even “background” lead exposure—what most people would consider normal—was enough to elevate cardiovascular risk.

Lead is an endothelial saboteur. It disrupts nitric oxide signaling (essential for keeping blood vessels relaxed), triggers inflammation, impairs the body’s ability to repair vascular damage, and promotes thrombosis. In a little-known but striking study, van Strijp and colleagues showed that exposing endothelial cells to lead in tissue culture caused visible tears and membrane blebs, clear signs of cellular injury. These findings suggest that lead initiates endothelial dysfunction—the first lesion in atherosclerosis.

So where does estrogen come in?

Opposing Forces: Estrogen and Lead

What first caught my attention wasn’t just that lead causes damage, but that its effects seem to mirror—in reverse—the benefits attributed to estrogen.

Estrogen promotes nitric oxide production; lead inhibits it. Estrogen repairs vascular injury; lead prevents repair. Estrogen helps reduce clot formation; lead encourages it. Even in terms of lipids, the patterns are striking: lead exposure is associated with higher LDL and triglycerides, while estrogen tends to have the opposite effect.

The symmetry is almost poetic—if you’re into biochemical poetry.

This observation raises a provocative possibility: Could estrogen’s cardiovascular benefits be due, at least in part, to its ability to reduce circulating lead?

As strange as it may sound, the evidence points in that direction.

Estrogen’s Quiet Side Job: Lead Management

It turns out that women—at least during their reproductive years—have lower blood lead levels than men. Before puberty, boys and girls have similar levels, but around menarche, when estrogen surges, girls’ blood lead levels drop by about 20%. They stay lower until menopause.

This decline isn’t random. Estrogen plays a central role in how the female body handles lead. For one, women lose a small amount of blood each month during menstruation—and with it, a little lead. Pregnant women offload lead to the fetus. The size of the postmenopausal lead rebound depends on pregnancy history. Women who’d had three or more children saw a much smaller rise in blood lead after menopause. But most importantly, estrogen helps sequester lead in the bones.

In adults, over 90% of the body’s lead burden is stored in the skeleton. Estrogen enhances bone formation and promotes the storage of lead in these newly built structures. It’s not a perfect system—no one wants lead in their bones—but it’s better than having it circulate through vital organs.

Studies show that women, unlike men, store significantly more lead in bone during their reproductive years. When estrogen levels fall at menopause, this storage strategy collapses. Bone resorption increases, and with it, stored lead begins to leach back into the bloodstream.

In other words, menopause doesn’t just mark the end of reproductive hormones. It may also signal the beginning of a slow, involuntary lead release.

Perimenopause: The Danger Zone

The timing is almost too neat. Bone loss after menopause follows a predictable pattern. The first three to four years are marked by accelerated bone resorption—up to five times the usual rate. This is when most bone loss occurs, and, it seems, when the biggest spike in blood lead levels happens.

Ellen Silbergeld, one of the pioneers in this field, found that perimenopausal women (ages 45–49) had the highest blood lead levels across all age groups. Other studies confirmed this pattern: women in early menopause had higher blood lead levels than those in later menopause.

A particularly telling study followed women undergoing surgical menopause. Within six months of oophorectomy (removal of the ovaries), blood lead levels rose significantly—especially among those who weren’t given estrogen therapy.

Estrogen therapy, it turns out, reduces bone turnover, and curbs the release of stored lead. This may explain why hormone therapy seems to help women who start it early, but not those who begin years after menopause. Once the lead is back in circulation, it may be too late.

This pattern aligns perfectly with the “timing hypothesis,” first proposed in the early 2000s, which holds that hormone therapy is beneficial when initiated near menopause but may be ineffective—or harmful—if started later.

The missing piece may not be the hormones themselves, but the metal hiding in women’s bones.

The Hormone Therapy Debacle (and Redemption?)

In the 1980s and early ’90s, hormone therapy was all the rage. Observational studies suggested that estrogen cut the risk of heart disease in half. Physicians embraced the idea with gusto. Estrogen became the most prescribed medication in the U.S.

Then came the fall.

Large randomized controlled trials, including the Women’s Health Initiative, found no cardiovascular benefit in older women taking hormone therapy—and in some cases, an increased risk. The backlash was swift. Estrogen prescriptions plummeted.

Critics of the earlier studies blamed healthy user bias or poor confounding control. Defenders of hormone therapy argued that the trials enrolled older women who already had atherosclerosis—too late for estrogen to help.

The timing hypothesis attempted to reconcile the conflict. Estrogen, the theory went, works best in women with healthy arteries. Once plaques are established, adding estrogen may do more harm than good.

But even this elegant theory lacked a clear biological mechanism—until lead entered the conversation.

The Lead-Estrogen Hypothesis offers a missing link: estrogen reduces cardiovascular risk in early menopause by preventing the release of bone-stored lead into the bloodstream. Start therapy early, and you keep the skeleton locked. Start late, and the vault has already been emptied.

What Comes Next?

The Lead-Estrogen Hypothesis isn’t a replacement for existing ideas—it’s a complement. It helps explain why estrogen protects women before menopause, why hormone therapy helps early initiators, and why that benefit disappears—or even reverses—in older women.

It also suggests that estrogen’s role as a cardiovascular protector may be partly indirect. By influencing bone turnover and lead metabolism, estrogen prevents the release of a known vascular toxin during a vulnerable period.

Future research should investigate the relationship between bone resorption, blood lead levels, and cardiovascular risk in perimenopausal women. And clinicians may want to consider bone turnover and environmental exposures when evaluating the risks and benefits of hormone therapy.

There’s more work to be done. But for now, the trail of evidence points to a new understanding of an old hormone—and a toxic metal that never quite left us alone.

An Unlikely Alliance

Estrogen and lead don’t sound like natural opposites. One is a hormone of youth and fertility; the other, a relic of industrial pollution. But in this unlikely pairing lies a deeper insight into women’s health.

Estrogen’s protection against heart disease may be partly due to its ability to keep lead out of circulation during the reproductive years. When estrogen declines, the floodgates open—at just the time when cardiovascular risk begins to rise.

It’s a sobering thought: that buried in our bones, beneath layers of calcified history, lies a heavy metal with unfinished business.

Contact the author for references to this article.